Skip to main content
Norris Cotton Cancer Center
In This Section

Recently Opened Clinical Trials for September 2014

James Rigas
Associate Professor
Molecular Therapeutics
EMD Serono
A multicenter, randomized, double-blind, placebo-controlled Phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC)

Convance, Inc
A randomized, double-blind Phase 2 study of ruxolitinib or placebo in combination with pemetrexed/cisplatin and pemetrexed maintenance for initial treatment of subjects with nonsquamous non-small cell lung cancer that is Stage IIIB with pleural/pericardial effusion, Stage IV, or recurrent

Pharmaceuticals LP
A Phase II, open label, single-arm study to assess the safety and efficacy of AZD9291 in patients with locally advanced/metastatic non-small cell lung cancer whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy and whose tumours are epidermal growth receptor mutation and T790M mutation positive